Nektar Therapeutics (NKTR) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to 268.63%.
- Nektar Therapeutics' EBIT Margin fell 1262700.0% to 268.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 156.69%, marking a year-over-year increase of 76400.0%. This contributed to the annual value of 106.88% for FY2024, which is 1857100.0% up from last year.
- Per Nektar Therapeutics' latest filing, its EBIT Margin stood at 268.63% for Q3 2025, which was down 1262700.0% from 324.21% recorded in Q2 2025.
- Over the past 5 years, Nektar Therapeutics' EBIT Margin peaked at 49.18% during Q4 2024, and registered a low of 708.07% during Q2 2022.
- In the last 5 years, Nektar Therapeutics' EBIT Margin had a median value of 268.63% in 2025 and averaged 320.47%.
- Per our database at Business Quant, Nektar Therapeutics' EBIT Margin crashed by -3190600bps in 2022 and then surged by 4612300bps in 2023.
- Over the past 5 years, Nektar Therapeutics' EBIT Margin (Quarter) stood at 451.48% in 2021, then skyrocketed by 47bps to 238.25% in 2022, then soared by 41bps to 140.3% in 2023, then surged by 135bps to 49.18% in 2024, then tumbled by -646bps to 268.63% in 2025.
- Its EBIT Margin was 268.63% in Q3 2025, compared to 324.21% in Q2 2025 and 425.76% in Q1 2025.